Compare SCLX & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | LNSR |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 142.0M |
| IPO Year | N/A | N/A |
| Metric | SCLX | LNSR |
|---|---|---|
| Price | $19.15 | $11.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 122.8K | 70.7K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $40,360,000.00 | ★ $59,141,000.00 |
| Revenue This Year | N/A | $19.55 |
| Revenue Next Year | $749.70 | $35.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.02 |
| 52 Week Low | $3.60 | $7.13 |
| 52 Week High | $34.27 | $17.31 |
| Indicator | SCLX | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 56.52 |
| Support Level | $18.34 | $10.14 |
| Resistance Level | $20.62 | $10.48 |
| Average True Range (ATR) | 2.22 | 0.46 |
| MACD | -0.02 | 0.20 |
| Stochastic Oscillator | 32.91 | 82.46 |
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.